Retatrutide 20mg

Triple GIP/GLP-1/Glucagon Receptor Agonist for Advanced Metabolic Research

Retatrutide 20mg provides pharmaceutical-grade triple incretin agonist for researchers conducting multi-phase metabolic studies, comparative efficacy trials, and in-depth investigation of synergistic GIP/GLP-1/Glucagon signaling. This budget-friendly versatile supply supports comprehensive research protocols examining maximal weight management, enhanced energy expenditure, and revolutionary metabolic regulation mechanisms that define the next generation of obesity and diabetes research.

Research Applications & Mechanisms

• Synergistic Triple Incretin Biology: Investigate complementary GIP, GLP-1, and glucagon receptor signaling, pathway convergence and synergy, tissue-specific receptor expression patterns, and unprecedented metabolic outcomes exceeding dual-agonist approaches
• Maximal Body Weight Reduction: Examine 24-28% weight loss mechanisms, sustained adiposity elimination, metabolic adaptation prevention, weight maintenance without rebound, and efficacy approaching bariatric surgery outcomes
• Glucagon Receptor-Mediated Metabolism: Study hepatic fat oxidation enhancement, lipolysis amplification, energy expenditure increase, thermogenic activation, and metabolic rate optimization unique to glucagon pathway activation
• Enhanced Beta-Cell & Glycemic Function: Explore triple incretin-mediated insulin secretion, superior HbA1c reduction, beta-cell preservation and proliferation, and diabetes intervention exceeding dual-agonist efficacy
• Hepatic Metabolic Transformation: Assess glucagon-driven hepatic fat mobilization, NASH/NAFLD resolution, liver fibrosis reduction, and hepatic metabolic health superior to GIP/GLP-1 dual agonism
• Cardiovascular & Metabolic Protection: Investigate comprehensive MACE reduction, endothelial function improvement, lipid profile optimization, and multi-organ protective effects
• Energy Balance & Thermogenesis: Study brown adipose tissue activation, thermogenic capacity enhancement, energy expenditure optimization, and metabolic flexibility improvement
• Multi-Organ Metabolic Coordination: Examine coordinated metabolic improvements across pancreas, liver, adipose tissue, skeletal muscle, cardiovascular system, kidney, and brain

Technical Specifications

• Purity: ≥98% 
• Structure: Engineered peptide with balanced triple GIP/GLP-1/Glucagon receptor agonist activity
• Molecular Weight: ~5,960 Da
• Form: Lyophilized white to off-white sterile powder
• Half-Life: ~6-7 days via fatty diacid albumin binding and DPP-4 resistance
• Receptor Activity: Triple agonist with balanced GIP, GLP-1, and glucagon receptor potency
• Solubility: Water-soluble; reconstitute in bacteriostatic water (pH 7.0-7.4 optimal)
• Storage: 2-8°C refrigerated; protect from light and freezing
• Stability: Stable for 24 months refrigerated; reconstituted solutions stable 28 days at 2-8°C
• Reconstitution: Add 2mL bacteriostatic water for 10mg/mL concentration
• Price per vial.
• Free shipping.
• All sales final.

Ideal Research Scenarios

The 20mg budget-friendly versatile supply is optimized for laboratories conducting dose-escalation protocols, multi-week metabolic studies, comparative triple versus dual incretin research, or comprehensive investigation of synergistic GIP/GLP-1/Glucagon biology representing the cutting edge of metabolic science.

Why Retatrutide Surpasses Dual Incretin Approaches

Retatrutide's addition of glucagon receptor activation to proven GIP/GLP-1 dual agonism creates a metabolic transformation unmatched by any previous incretin-based approach. Glucagon's role in hepatic fat oxidation, energy expenditure, and lipolysis complements GIP's adipocyte sensitization and GLP-1's appetite suppression, producing weight loss approaching 28%—significantly exceeding the 20-25% achieved with dual agonists. This represents the first pharmacological intervention to rival bariatric surgery efficacy, making Retatrutide the gold standard for researchers investigating the future of obesity and metabolic disease therapeutics.

For research use only. Not for human consumption, therapeutic application, or weight management.